

ABSTRACT TEMPLATE for Company Presentations

The maximum number of words for this abstract is 300 words.

You may delete the section instructions, leaving only the bolded bullet title.

Questions for categories: Biotech/Pharma or Medical Devices or Health IT/Digital

Answers should not exceed 60 words per question

- **Investment Rational**
Sequentify, a DNA sequencing startup from Weizmann Institute, is democratizing genomics by reducing time and cost of library preparation using unique synthetic biology, enabling NGS targeted sequencing at ~3.5 hours lab time and fraction of the cost of others.
Markets include cancer diagnostics, carrier screening, COVID19 mutation, agritech and virology. Management includes world class scientists industry business executive.
- **Business Strategy**
Sequentify enables hospitals, HMOs and health organizations perform sequencing in-house, by providing kits to enable rapid NGS. The company is already growing its customers and revenues fast, with multiple large orders, solving real pain around library preparation manual work and costs, and is working on R&D to support longer term growth around WGS.
- **Core Technology**
The core technology is Sequentify's InfiniSeq platform, which is based on unique synthetic biology process that enables capturing effectively just the genomic targets of interest, while maintaining high sensitivity, multiplexity and accuracy even in problematic GC rich areas. Our mission is the enable genomics diagnostics at scale, as common and affordable as blood counts.
- **Product Profile/Pipeline**
Sequentify is already selling kits and panels for several applications, including hereditary cancer diagnostics, carrier screening, primates screening, COVID19 mutation and others. The company provides the chemistry, protocol and software, supporting Illumina sequencers. Customers are now validating the deliverables, with 600% revenues growth expected this year.
- **What's Next?**
R&D to improve NGS InfiniSeq protocols, support virology and other applications
Validation, clinical and non-clinical for generated panels
Delivering to signed customers
Closing large partnership – sequencing platforms, genomic software partners, and pharma companies
Raising pre-round A SAFE (in progress) to support fast growth